OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi in Immuno-Oncology at ASCO 2022

23.05.2022 - Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring ... Seite 1

Related Keywords

Roma , Lazio , Italy , , Lille University Hospital , Gustave Roussy Institute , Progress Poster Presentations , Gustave Roussy Cancer Campus , Open Label , After First Line , Istituto Nazionale Tumori Regina Elena , Ose Immunotherapeutics ,